SEC Tracker
Get the app
AMRN · XBRL financial data

Amarin financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AMRN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers75*57674262*42735049*454240
Gross profit—324316—255022—181516
Research and development6*6556*5545*554
Selling, general and administrative44*40393737*37392020*212214
General and administrativeyear only991010*915912*11147
Total operating expenses50*45434143*42663329*292719
Operating income (loss)(5)*(14)(1)(25)(53)*(17)(16)(11)(6)*(11)(12)(2)
Interest incomeyear only———year only3333*232
Interest expenseyear only———year only———year only———
Other income (expense)(1)*200(1)*0(0)03*010
Income tax expense (benefit)3*114(1)*21(0)0*2(0)0
Net income (loss)(6)*(10)2(25)(49)*(16)(14)(8)(1)*(11)(8)0
Earnings per share, basic USD per share(0.01)*(0.02)0.00(0.06)(0.12)*(0.04)(0.03)(0.02)0.00*(0.03)(0.02)0.00
Earnings per share, diluted USD per share(0.01)*(0.02)0.00(0.06)(0.12)*(0.04)(0.03)(0.02)0.00*(0.03)(0.02)0.00
Weighted average shares, basic millions of shares408*410411411412*413414416416*419416418
Weighted average shares, diluted millions of shares408*410411411411*413414416416*419416428

Balance sheet

CSV

Fiscal quarters (AMRN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents199214216157121120148123135131144157
Short-term investments1219491149173162151164168177171167
Accounts receivable13411612411312210711912712710893112
Inventory259255239224166159171185196184164159
Prepaid and other current assets1283271325172924263119
Total current assets725688702650595573607628650626603613
Property and equipment, net000000000———
Right-of-use asset888888876666
Total assets832790800751685656670660671646624634
Accounts payable536854414046453745481940
Total current liabilities259224231202180162186182194180164175
Lease liability, non-current988888776655
Total liabilities280244248219199182205201211196181190
Accumulated deficit(1,586)(1,596)(1,595)(1,620)(1,669)(1,684)(1,698)(1,706)(1,707)(1,718)(1,726)(1,725)
Total stockholders' equity552546552531486474465459459449444444
Total liabilities and equity832790800751685656670660671646624634
Common shares outstanding (cover page) millions of shares409411411411412414415416416420420422

Cash flows

CSV

Fiscal quarters (AMRN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(6)*(10)2(25)(49)*(16)(14)(8)(1)*(11)(8)0
Stock-based compensation5*54*5*3*46*2*2*22*1*
Net cash from operating activities(1)*(13)(3)*(2)*(13)*(12)17*(13)*15*67*9*
Net cash from investing activities(71)*295*(57)*(23)*1212*(12)*(4)*(8)6*5*
Proceeds from issuing common stock———0*————————
Net cash from financing activities0*(1)0*(0)*0*(1)(1)*(0)*(0)*(2)(0)*(1)*
Net change in cash(72)*152*(59)*(36)*(2)28*(25)*12*(4)12*13*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Amarin157409.2*not reported— 10-QSep 30, 2026
Rigel Pharmaceuticals617931*18.7M— 10-QJun 30, 2026
Northwest Biotherapeutics0.60.8(7.2)*1.7B0.1 quarters 10-QJun 30, 2026
Usana Health Sciences16922323*18.5M— 10-QJul 4, 2026
Emergent BioSolutions176110100*51.4M— 10-QSep 30, 2026
Altimmune63not reported(24)*194.5M13.5 quarters 10-QJun 30, 2026
Prothena Corp Public2881(25)*51.3M11.5 quarters 10-QJun 30, 2026
Aura Biosciences68not reported(33)*103.7M2.1 quarters 10-QJun 30, 2026
Nektar Therapeutics3910(76)*34.1M9.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.